Investigational antifungal agents for invasive mycoses: a clinical perspective.

Details

Serval ID
serval:BIB_90F243509573
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Investigational antifungal agents for invasive mycoses: a clinical perspective.
Journal
Clinical infectious diseases
Author(s)
Lamoth F., Lewis R.E., Kontoyiannis D.P.
ISSN
1537-6591 (Electronic)
ISSN-L
1058-4838
Publication state
Published
Issued date
05/01/2022
Peer-reviewed
Oui
Language
english
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Abstract
Treatment of invasive fungal infections (IFI) remains challenging, because of the limitations of the current antifungal agents (i.e. mode of administration, toxicity, drug-drug interactions), and the emergence of resistant fungal pathogens. Therefore, there is an urgent need to expand our antifungal armamentarium. Several compounds are reaching the stage of phase II or III clinical assessment. These include new drugs within the existing antifungal classes or displaying similar mechanism of activity with improved pharmacologic properties (rezafungin, ibrexafungerp) or first-in-class drugs with novel mechanisms of action (olorofim, fosmanogepix). Although critical information regarding the performance of these agents in heavily immunosuppressed patients is pending, they may provide useful additions to current therapies in some clinical scenarios, including IFI caused by azole-resistant Aspergillus or multi-resistant fungal pathogens (e.g. Candida auris, Lomentospora prolificans). However, their limited activity against Mucorales and some other opportunistic molds (e.g. some Fusarium spp.) persists as a major unmet need.
Keywords
APX001, CD101, E1211, F901318, SCY078, VT-1129, VT-1161, VT-1598
Pubmed
Create date
10/01/2022 9:27
Last modification date
11/01/2022 6:34
Usage data